Skip to main content
Premium Trial:

Request an Annual Quote

ABI, BioTrove Collaborate on Integrated Genotyping Platform

NEW YORK (GenomeWeb News) – Applied Biosystems and BioTrove have struck two agreements that cover the integration and marketing of genotyping and gene-expression applications, as well as other genomics tools, the firms said today.
 
Under one agreement, ABI will develop and market custom arrays of TaqMan SNP genotyping assays pre-loaded on BioTrove’s OpenArray, which is a flexible array format that allows researchers to perform over 3,000 different high-throughput genotyping assays in different configurations, ABI said.
 
This integrated platform will enable researchers to conduct high-throughput genotyping studies at a “lower total cost compared to commercially available methods,” ABI said. 
 
ABI also will hold the rights to sell all genotyping applications, including some not based on its Taqman technology, for the OpenArray. The company expects to begin selling these tools in the second half of 2008.
 
ABI said the integrated Taqman and OpenArray platform will enable an end-to-end genotyping workflow of less than four hours, thus allowing researchers to analyze thousands of samples for large-scale genotyping projects in days rather than weeks.
 
The agreement also gives ABI an option to collaborate with BioTrove to develop and market the OpenArray for high-throughput gene-expression applications.
 
A second agreement gives BioTrove a worldwide license to ABI’s patents covering real-time thermal cyclers, microfluidics, and data analysis. This contract will allow BioTrove to make and sell real-time thermal cyclers and array sample loaders for life science research purposes and to develop more real-time PCR applications for the OpenArray, ABI added.
 
Financial terms of the agreements were not released.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.